• Addex Therapeutics held its 2026 annual general meeting on June 30, 2026.
• Shareholders adopted the 2025 annual report, consolidated financial statements, annual financial statements, and the proposed appropriation of results.
• A consultative vote endorsed the 2025 compensation report.
• Discharge was granted to board members and executive management for their activities during 2025.
• Shareholders adopted amendments to the articles of association to increase the capital band and the conditional share capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300100PRIMZONEFULLFEED1001210244) on June 30, 2026, and is solely responsible for the information contained therein.